IND Safety Reporting Rule Delayed After PhRMA Asks For More Harmonization
Executive Summary
FDA has made the unusual decision to delay implementation of its new IND safety reporting rules, saying it will "exercise enforcement discretion" on the matter until Sept. 28 following a meeting with the Pharmaceutical Research and Manufacturers of America.
You may also be interested in...
FDA IND Safety Reporting Rule: New Types Of Data Must Be Submitted
Sponsors will have to provide new information to FDA under the agency’s final rule on investigational new drug safety reporting requirements.
FDA's Final Rule On IND Safety Reporting Encourages More Limited Submissions
Revisions emphasize the types of evidence that suggest a causal relationship between the drug and adverse event.
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
FDA's safety reporting rule would require drug and biologic sponsors to review any safety information acquired from a foreign regulatory authority to determine whether it should be reported to the agency